Calliditas Therapeutics AB (publ) Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$2.06 | -$2.06 | -$2.06 |
| Q2 2024 | 1 | -$1.15 | -$1.15 | -$1.15 |
| Q3 2024 | 2 | -$1.18 | $3.53 | $1.47 |
| Q4 2024 | 1 | $4.22 | $4.22 | $4.22 |
| Q1 2025 | 1 | $3.39 | $3.39 | $3.39 |
| Q2 2025 | 1 | $4.12 | $4.12 | $4.12 |
| Q3 2025 | 1 | $4.46 | $4.46 | $4.46 |
| Q4 2025 | 1 | $4.68 | $4.68 | $4.68 |
Calliditas Therapeutics AB (publ) Earnings Date And Information
Calliditas Therapeutics AB (publ) last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.16 earnings per share for the quarter, missing analysts' consensus estimates of $-0.13 by $0.03. The company had revenue of 559.78 M for the quarter and had revenue of 1.21 B for the year. Calliditas Therapeutics AB (publ) has generated $-9 earnings per share over the last year ($-8.69 diluted earnings per share) and currently has a price-to-earnings ratio of -48.19. Calliditas Therapeutics AB (publ) has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based on prior year's report dates.
Calliditas Therapeutics AB (publ) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2024 | Q2 2024 | -$0.13 | -$0.88 | -0.75 | $454.87 M | $559.78 M |
| 04/25/2024 | Q1 2024 | -$9.17 | $295.48 M | |||
| 04/24/2024 | Q4 2023 | -$0.34 | $451.56 M | |||
| 09/29/2023 | Q3 2023 | -$3.14 | $325.21 M | $294.59 M | ||
| 08/17/2023 | Q2 2023 | -$0.25 | -$1.71 | -1.46 | $292.22 M | $269.38 M |
| 04/28/2023 | Q1 2023 | -$3.49 | $191.35 M | |||
| 04/26/2023 | Q4 2022 | -$0.07 | $429.04 M | |||
| 09/29/2022 | Q3 2022 | -$0.34 | $132.95 M | $260.06 M | ||
| 04/29/2022 | Q2 2022 | -$7.24 | $80.21 M | $64.05 M | ||
| 04/29/2022 | Q1 2022 | -$7.91 | $49.73 M | |||
| 04/27/2022 | Q4 2021 | -$8.37 | $31.18 M | |||
| 09/29/2021 | Q3 2021 | $0.25 | $198.17 M | |||
| 06/29/2021 | Q2 2021 | -$6.40 | $0 | |||
| 03/30/2021 | Q1 2021 | -$5.02 | $0 | |||
| 04/27/2021 | Q4 2020 | -$6.83 | $400,000 | |||
| 09/29/2020 | Q3 2020 | -$5.54 | $0 | |||
| 06/29/2020 | Q2 2020 | -$3.00 | $0 | |||
| 03/30/2020 | Q1 2020 | -$3.29 | $474,000 | |||
| 12/30/2019 | Q4 2019 | -$0.60 | $46.59 M | |||
| 09/29/2019 | Q3 2019 | -$2.60 | $0 |
Calliditas Therapeutics AB (publ) Earnings: Frequently Asked Questions
-
When is Calliditas Therapeutics AB (publ)'s earnings date?
Calliditas Therapeutics AB (publ) has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based off last year's report dates.
-
How can I listen to Calliditas Therapeutics AB (publ)'s earnings conference call?
The conference call for Calliditas Therapeutics AB (publ)'s latest earnings report can be listened to online.
-
How can I read Calliditas Therapeutics AB (publ)'s conference call transcript?
The conference call transcript for Calliditas Therapeutics AB (publ)'s latest earnings report can be read online.
-
How much revenue does Calliditas Therapeutics AB (publ) generate each year?
Calliditas Therapeutics AB (publ) (:CALT) has a recorded annual revenue of $1.21 B.
-
How much profit does Calliditas Therapeutics AB (publ) generate each year?
Calliditas Therapeutics AB (publ) (:CALT) has a recorded net income of $1.21 B. Calliditas Therapeutics AB (publ) has generated $-8.69 earnings per share over the last four quarters.
-
What is Calliditas Therapeutics AB (publ)'s price-to-earnings ratio?
Calliditas Therapeutics AB (publ) (:CALT) has a price-to-earnings ratio of -48.19 and price/earnings-to-growth ratio is -8.34.
